Harpoon Therapeutics Presents Updated Interim Clinical Data for the PSMA-targeting TriTAC® HPN424 at the 2021 ASCO Annual Meeting
June 04, 2021 09:00 ET
|
Harpoon Therapeutics
The ongoing dose escalation Phase 1/2a trial has enrolled 89 patients with progressive, metastatic castration-resistant prostate cancer in 13 cohorts.Safety data continues to show that HPN424 is...
Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
June 03, 2021 17:00 ET
|
Coherus BioSciences, Inc.
– In pivotal Phase 3 JUPITER-02 study, toripalimab plus chemotherapy significantly improved PFS compared to chemotherapy alone in high and low PD-L1 expression subgroups – – Although median overall...
PDS Biotechnology Expands VERSATILE-002 study of PDS0101 and KEYTRUDA® in Advanced Head and Neck Cancer to Include Patients Who Have Failed Prior Treatment with Checkpoint Inhibitors
June 03, 2021 08:53 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., June 03, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease...
PDS Biotechnology Establishes Partnership With Head and Neck Cancer Alliance
May 27, 2021 07:30 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a novel therapy for HPV-associated cancer based...
Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613® (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program
May 26, 2021 09:00 ET
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced...
PDS Biotech to Host Company Conference Call Following Oral Presentation of PDS0101 Data at 2021 ASCO Annual Meeting
May 24, 2021 08:07 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., May 24, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s...
AB Science annonce aujourd'hui que les résultats de l’étude AB12005 du masitinib dans le cancer du pancréas ont été sélectionnés pour être présentés à la prochaine réunion annuelle de l'ASCO.
May 20, 2021 12:07 ET
|
AB Science
COMMUNIQUE DE PRESSE SELECTION POUR PRESENTATION A LA REUNION ANNUELLE DE L’ASCO DES RESULTATS DE L’ETUDE AB12005 DU MASITINIB DANS LE CANCER DU PANCREAS Paris, 20 mai 2021, 18h AB Science SA...
AB Science today announced that results from masitinib study AB12005 in pancreatic cancer, have been selected for presentation at the upcoming ASCO Annual Meeting
May 20, 2021 12:07 ET
|
AB Science
PRESS RELEASE RESULTS FROM MASITINIB STUDY AB12005 IN PANCREATIC CANCER SELECTED FOR PRESENTATION AT THE ASCO ANNUAL MEETING Paris, May 20, 2021, 6pm CET AB Science SA (Euronext - FR0010557264 -...
PDS Biotech Announces Release of Abstract for PDS0101 in NCI-Led Phase 2 Clinical Study for Oral Presentation at 2021 ASCO Meeting
May 20, 2021 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., May 20, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s...
CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody CTL-002 at the 2021 ASCO Annual Meeting
May 20, 2021 03:30 ET
|
CatalYm GmbH
MUNICH, Germany, May 20, 2021 (GLOBE NEWSWIRE) -- CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced that their abstract with first interim data from...